Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies

Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has conseque...

Full description

Bibliographic Details
Main Authors: Roberto Pili, Leigh Ellis
Format: Article
Language:English
Published: MDPI AG 2010-08-01
Series:Pharmaceuticals
Subjects:
cancer
epigenetics
epigenetic therapy
HDAC
HDAC inhibitors
apoptosis
angiogenesis
autophagy
pre-clinical
clinical trial
Online Access:http://www.mdpi.com/1424-8247/3/8/2441/

Internet

http://www.mdpi.com/1424-8247/3/8/2441/

Similar Items